Leadership
The COPDforum leadership is comprised of renowned researchers/clinicians in COPD, who have contributed significantly
to the developments in this field. This global group represents some of the world's thought leaders in this area,
who are prominent in respiratory publications, international and local societies and research initiatives. Click on the
links below to learn more about the COPDforum leadership.
Leadership
Roland Buhl
MD, PhD, Professor of Medicine
Germany
Place of work
Mainz University Hospital.
Experience
Roland Buhl is Professor of Medicine and Head of the Pulmonary Department at Mainz University Hospital. He qualified and received his doctorate from the University of Heidelberg and later trained in pulmonary medicine and allergology, first in Berlin and Frankfurt, and then at National Institutes of Health, USA, before receiving his Ph.D. from the University of Frankfurt.
Professor Buhl is a member of the German Society of Internal Medicine, the German Society of Pneumology, the Society of Respiratory Research, the European Respiratory Society and the American Thoracic Society. He has received numerous honours and awards including many teaching awards and Fellowship of the International Molecular Medicine Foundation.
A selection of Professor Buhl’s most recent publications are listed below.
Recent publications
Achenbach T, Weinheimer O, Biedermann A, Schmitt S, Freudenstein D, Goutham E, Kunz RP, Buhl R, Dueber C, Heussel CP. MDCT assessment of airway wall thickness in COPD patients using a new method: correlations with pulmonary function tests. Eur Radiol 2008 Jul 19. [Epub ahead of print]
Kuemmel A, Single K, Bittinger F, Faldum A, Schmidt LH, Sebastian M, Micke P, Taube C, Buhl R, Wiewrodt R. TA-MUC1 epitope in non-small cell lung cancer. Lung Cancer 2008 Jun 6. [Epub ahead of print]
Fischer B, Buhl R. [Lung cancer.] Med Klin (Munich) 2008;103(5):311–20.
Korn S, Vogelmeier C, Buhl R. [Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma.] Med Klin (Munich) 2008;103(5):299–310.
Taube C, Buhl R. [Immunomodulation therapy for allergic asthma. What is already possible, what is to come?] Dtsch Med Wochenschr 2008;133(14):727–32.
Gillissen A, Buhl R, Kardos P, Puhan M, Rabe KF, Rothe T, Sauer R, Welte T, Worth H, Menz G. [Trial end-point in chronic obstructive pulmonary disease (COPD): minimal clinically important difference.] Pneumologie 2008;62(3):149–55.
Reuter S, Heinz A, Sieren M, Wiewrodt R, Gelfand EW, Stassen M, Buhl R, Taube C. Mast cell-derived tumour necrosis factor is essential for allergic airway disease. Eur Respir J 2008;31(4):773–82.
Grönke L, Beeh KM, Cameron R, Kornmann O, Beier J, Shaw M, Holz O, Buhl R, Magnussen H, Jörres RA. Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008;21(2):409–17.
Thomeer M, Demedts M, Behr J, Buhl R, Costabel U, Flower CD, Verschakelen J, Laurent F, Nicholson AG, Verbeken EK, Capron F, Sardina M, Corvasce G, Lankhorst I; Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study group. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J 2008;31(3):585–91.
Kuemmel A, Single K, Bittinger F, Faldum A, Schmidt LH, Sebastian M, Taube C, Buhl R, Wiewrodt R. The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer. Tumour Biol 2007;28(6):340–9.
Radsak MP, Taube C, Haselmayer P, Tenzer S, Salih HR, Wiewrodt R, Buhl R, Schild H. Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease. Clin Dev Immunol 2007;2007:52040.
Buhl R, Vogelmeier C. Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. Curr Med Res Opin 2007;23(8):1867–78.